Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation

Journal of Nutrigenetics and Nutrigenomics

Volumn 6, Issue 2, 2013, Pages 73-82

  Thifault, Elisabeth ^a   Cormier, Hubert ^a   Bouchard Mercier, Annie ^a   Rudkowska, Iwona ^a   Paradis, Ann Marie ^a   Garneau, Veronique ^a   Ouellette, Catherine ^a   Lemieux, Simone ^a,b   Couture, Patrick ^a,b   Vohl, Marie Claude ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease risk factors; n 3 polyunsaturated fatty acids; Plasma lipids

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FISH OIL; GLUCOSE; ICOSAPENTAENOIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; AGE; BODY MASS; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; FEMALE; FOOD GUIDE PYRAMID; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SEX; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASE; DIETARY INTAKE; METABOLISM; RISK FACTOR; SUPPLEMENTATION;

AGE FACTORS; AGED; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 84877852025     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000350744     Document Type: Review

References (55)

1. Tracking Heart Disease and Stroke in Canada, 2009. http://www.phac-aspc. gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf (accessed April 15, 2013).
2. Gupta R, Misra A, Vikram NK, Kondal D, Gupta SS, Agrawal A, Pandey RM: Younger age of escalation of cardiovascular risk factors in Asian Indian subjects. BMC Cardiovasc Disord 2009; 9: 28.
3. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-2757. (Pubitemid 35364932)
4. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-761. (Pubitemid 19234807)
5. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:e20-e30.
6. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, et al: Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006; 332: 752-760.
7. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098. (Pubitemid 46483662)
8. Silverberg DS, Schwartz D: The role of iron, omega-3 fatty acids, and vitamins in heart failure. Curr Treat Options Cardiovasc Med 2012; 14: 328-341.
9. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30. (Pubitemid 44468073)
10. Chin JP, Gust AP, Nestel PJ, Dart AM: Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993; 21: 22-28. (Pubitemid 23006448)
11. Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65(5 suppl):1645S- 1654S. (Pubitemid 27187958)
12. Mori TA: Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006; 33: 842-846. (Pubitemid 44215141)
13. Defilippis AP, Blaha MJ, Jacobson TA: Omega-3 fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med 2010; 12: 365-380.
14. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE: Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21: 494-500. (Pubitemid 28172922)
15. Montori VM, Farmer A, Wollan PC, Dinneen SF: Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23: 1407-1415.
16. Johnson JL, Slentz CA, Duscha BD, Samsa GP, McCartney JS, Houmard JA, Kraus WE: Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 2004; 176: 371-377. (Pubitemid 39369528)
17. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, Grundy SM, Johnson CL: Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773-1781. (Pubitemid 41434623)
18. McNamara RK, Able J, Jandacek R, Rider T, Tso P: Gender differences in rat erythrocyte and brain docosahexaenoic acid composition: role of ovarian hormones and dietary omega-3 fatty acid composition. Psychoneuroendocrinology 2009; 34: 532-539.
19. Decsi T, Kennedy K: Sex-specific differences in essential fatty acid metabolism. Am J Clin Nutr 2011; 94(6 suppl):1914S-1919S.
20. Mueller BA, Talbert BL, Tegeler CH: Comparative effects of omega-3 fatty acids in men and women. Clin Pharm 1989; 8: 328-329. (Pubitemid 19138077)
21. Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, et al: Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 2008; 88: 618-629.
22. Huebbe P, Schaffer S, Jofre-Monseny L, Boesch-Saadatmandi C, Minihane AM, Muller WE, Eckert GP, Rimbach G: Apolipoprotein E genotype and alpha-tocopherol modulate amyloid precursor protein metabolism and cell cycle regulation. Mol Nutr Food Res 2007; 51: 1510-1517.
23. Sarkkinen E, Korhonen M, Erkkila A, Ebeling T, Uusitupa M: Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 1998; 68: 1215-1222. (Pubitemid 28550951)
24. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA, Williams CM: ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1990-1997. (Pubitemid 30648814)
25. Goulet J, Nadeau G, Lapointe A, Lamarche B, Lemieux S: Validity and reproducibility of an interviewer-administered food frequency questionnaire for healthy French-Canadian men and women. Nutr J 2004; 3: 13.
26. Callaway CW: CWBC Standardization of Anthropometric Measurements. The Airlie (VA) Consensus Conference. Champaign, IL, Human Kinetics Publishers, 1988.
27. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8. (Pubitemid 17095867)
28. Burstein M, Samaille J: On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin Chim Acta 1960; 5: 609.
29. Warnick GR, Albers JJ, Bachorik PS, Turner JD, Garcia C, Breckinridge C, Kuba K, McNeely S, Hillerman G, King P, et al: Multilaboratory evaluation of an ultrafiltration procedure for high density lipoprotein cholesterol quantification in turbid heparin-manganese supernates. J Lipid Res 1981; 22: 1015-1020. (Pubitemid 11029364)
30. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
31. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, Lamarche B: Age and duration of followup as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001; 161: 2474-2480. (Pubitemid 33043121)
32. Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
33. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971; 33: 732-738.
34. Richterich R, Dauwalder H: Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971; 101: 615-618.
35. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548. (Pubitemid 20107994)
36. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, et al: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 2292-2333.
37. WHO: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. WHO, 2000.
38. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155: 487-495. (Pubitemid 34208040)
39. Robitaille N, Cormier G, Couture R, Bouthillier D, Davignon J, Perusse L: Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Hum Biol 1996; 68: 357-370. (Pubitemid 126448362)
40. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG: Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011; 93: 243-252.
41. Olano-Martin E, Anil E, Caslake MJ, Packard CJ, Bedford D, Stewart G, Peiris D, Williams CM, Minihane AM: Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 2010; 209: 104-110.
42. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ: Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007-1015. (Pubitemid 35244671)
43. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-1094. (Pubitemid 30230554)
44. Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, et al: Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007; 86: 1670-1679. (Pubitemid 350232182)
45. Griffin MD, Sanders TA, Davies IG, Morgan LM, Millward DJ, Lewis F, Slaughter S, Cooper JA, Miller GJ, Griffin BA: Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 years: the OPTILIP Study. Am J Clin Nutr 2006; 84: 1290-1298. (Pubitemid 44912809)
46. Fink RI, Kolterman OG, Griffin J, Olefsky JM: Mechanisms of insulin resistance in aging. J Clin Invest 1983; 71: 1523-1535. (Pubitemid 13056757)
47. Karlstrom BE, Jarvi AE, Byberg L, Berglund LG, Vessby BO: Fatty fish in the diet of patients with type 2 diabetes: comparison of the metabolic effects of foods rich in n-3 and n-6 fatty acids. Am J Clin Nutr 2011; 94: 26-33.
48. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U: Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996; 45: 947-953.
49. Guarner-Lans V, Rubio-Ruiz ME, Perez-Torres I, Banos de MacCarthy G: Relation of aging and sex hormones to metabolic syndrome and cardiovascular disease. Exp Gerontol 2011; 46: 517-523.
50. Kofler BM, Miles EA, Curtis P, Armah CK, Tricon S, Grew J, Napper FL, Farrell L, Lietz G, Packard CJ, et al: Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis 2012; 221: 467-470.
51. Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT: Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med 2002; 34: 481-488. (Pubitemid 36114367)
52. Trottier J, Caron P, Straka RJ, Barbier O: Profile of serum bile acids in noncholestatic volunteers: genderrelated differences in response to fenofibrate. Clin Pharmacol Ther 2011; 90: 279-286.
53. Masson LF, McNeill G: The effect of genetic variation on the lipid response to dietary change: recent findings. Curr Opin Lipidol 2005; 16: 61-67. (Pubitemid 40333368)
54. Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137-147. (Pubitemid 38937836)
55. Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454.